UBS expects Procter & Gamble to report stronger sales momentum in its fiscal Q1 2027 results on October 22, driven by improving US consumption trends and steady European growth. UBS forecasts organic sales growth of 2.6%, above Street expectations of 2.0%, with earnings per share around $1.85. The firm maintains its Buy rating and $172 price target, seeing P&G on track to meet its fiscal 2027 guidance of 1-3% organic sales growth and flat to 3% core EPS growth. Cost pressures remain a concern, but improving consumption and easier comparisons should support consistent growth.
Procter & Gamble shares are trading at USD 158.41 on Pluang as of Oct 17, 2026 01:41 WIB, showing a modest 0.86% gain in the past day. Despite the platform's order activity leaning heavily towards selling at 79%, the stock remains close to its 52-week high of USD 167.18. This trading context highlights investor caution even as UBS anticipates stronger sales momentum in P&G's upcoming fiscal Q1 report.
Jim Cramer and financial analysts recommend investors diversify portfolios with stable, dividend-paying stocks like consumer staples, pharmaceuticals, and waste management to protect against tech sector downturns. These 'quiet winners' continue to de...
Five companies selling everyday essentials like toothpaste, detergent, and soda—Coca-Cola, PepsiCo, Procter & Gamble, Colgate-Palmolive, and Kimberly-Clark—are maintaining or increasing their dividend payouts. These firms benefit from steady demand f...
Procter & Gamble leads with 70 consecutive years of dividend increases, joined by T. Rowe Price, Cisco Systems, Medtronic, and Johnson & Johnson, all known for steady dividend growth backed by strong cash flow. These companies maintain payout ratios ...
Procter & Gamble is showing signs of recovery with stabilized market share and improving trends in both U.S. and international markets. The company’s focus on consumer-led innovation and digital marketing is driving user growth, alongside product upg...
